גודל המנה ותדירות המתן: שיטות לקביעתן

Dose size is calculated based on achieving average steady-state blood levels within the therapeutic window—the range between minimum effective and minimum toxic concentrations. The calculation considers the drug's pharmacokinetic and pharmacodynamic properties, along with patient-specific factors including age, weight, organ function, and comorbidities. Optimal dose sizing minimizes plasma level fluctuations while maintaining efficacy.

Dosing frequency maintains effective drug levels by determining the interval between doses. A drug's half-life dictates how frequently it must be administered. Shorter half-lives require more frequent dosing to prevent plasma concentrations from dropping below the minimum effective level, while longer half-lives allow less frequent dosing intervals.

Drugs with wide therapeutic indices, like penicillin, tolerate larger doses taken less frequently without risking toxicity. Conversely, drugs with narrow therapeutic indices, such as digoxin, require smaller, more frequent doses to maintain steady plasma levels within a narrow therapeutic window. This distinction directly influences dosing regimen design.

Pharmacokinetic models use mathematical equations to predict drug concentrations over time by considering absorption, distribution, metabolism, and excretion. Clinicians apply these models to simulate various dosing scenarios and identify the regimen achieving desired therapeutic outcomes. Concentration-time curves visualize how dose size and frequency variations alter plasma concentration profiles.

Changes in dose size or dosing frequency directly affect plasma drug concentration, potentially altering the safety and efficacy of the dosing regimen. Smaller doses minimize fluctuations while maintaining efficacy, whereas higher doses create greater fluctuations and increased toxicity risk. Adjustments must align with therapeutic goals and specific drug properties.

Drug half-life measures the time required for plasma concentration to reduce by half, directly determining optimal dosing frequency. Drugs with shorter half-lives necessitate more frequent dosing to maintain efficacy without surpassing the toxic threshold. Understanding half-life allows clinicians to design regimens that keep plasma concentrations within the therapeutic window.

Dose size determination considers patient-specific factors including age, weight, organ function, and comorbidities alongside the drug's pharmacokinetic properties. These factors influence how the body absorbs, distributes, metabolizes, and excretes the drug. Individualized dosing ensures plasma concentrations remain within the therapeutic window for optimal safety and efficacy.